The Evaluation of PMP22 and Protein 0, Examinations for Early Disability Detection in Leprosy Patients by Widasmara, Dhelya et al.
174 
 
The Evaluation of PMP22 and Protein 0, Examinations 
for Early Disability Detection in Leprosy Patients 
 
Dhelya WIDASMARA1) *), Indropo AGUSNI2), Agus TURCHAN3), Sri Linuwih M4), 
 
1) Department of Dermatovenereology, Faculty of Medicine of Brawijaya University/dr. Saiful Anwar 
Regional General Hospital, Malang 
2) Department of Dermatovenereology, Faculty of Medicine of Airlangga University/dr. Soetomo 
Regional General Hospital, Surabaya 
3) Department of Neurosurgery, Faculty of Medicine of Airlangga University/dr. Soetomo Regional 
General Hospital, Surabaya 
4) Department of Dermatovenereology, Faculty of Medicine of Indonesia University/Cipto 
Mangunkusumo General Hospital, Jakarta 
 
Introduction: Leprosy is a chronic infectious disease caused by Mycobacterium leprae that has a 
predilection for peripheral nerves, especially Schwann cells. Leprosy medications may only eradicate 
the bacteria without preventing or recovering peripheral nerve damage. Previous studies proved that 
Krox-20 could be a useful diagnostic tool for early peripheral nerve damage detection in 
leprosy.nObjective: To analyse and to determine PMP22, and P0 cut-off points as diagnostic tools of 
early disability in leprosy. Methods: We examined ambulatory patients at Kediri Leprosy Hospital, 
Indonesia. We employed WHO’s criteria to assess the degree of disability and measured the study 
variables using ELISA. We then determine the cut-off value using Receiver Operating Characteristic 
curve. Results: From overall patients (n=79), 36 patients had 0-degree of disability, and 43 patients 
had 1-degree of disability. The ROC curve analysis revealed cut-off values for PMP22 and P0 at 4,42 
pg/mL and 11,39 pg/mL, respectively. The mean value for all variables in patients with 0-degree of 
disability were higher than that in patients with 1-degree of disability at 12,56 pg/mL vs 4,24 pg/mL 
(p<0,05) and at  9,85 pg/mL vs 2,86 pg/mL, respectively (p<0,05). Conclusion: Leprosy is a chronic 
infectious disease that brings forth many degrees of disability secondary to peripheral nerve invasion, 
particularly Schwann cells. Hence, early detection of peripheral nerve damage becomes crucial. The 
evaluation of PMP22 and P0 examinations is useful to identify early peripheral nerve damage in 
leprosy. 
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Leprosy is a chronic infectious disease caused by 
Mycobacterium leprae and has a predilection for 
the skin and peripheral nerves, especially in 
Schwann cells (1-4). Furthermore, leprosy is also 
cited as the most frequent aetiology of peripheral 
neuropathy.4 Approximately 2-3 million people 
globally have suffered from defects secondary to 
the disease. A large number of global leprosy 
incidents in the world is caused, amongst many, by 
inadequate access to health services and the 
challenges faced by health workers to reach the 
patients in isolated areas. Owing to late diagnosis 
and management common in the countryside, 
many have become disabled, both due to the past 
and the newly acquired infections. Additionally, 
the vaccine for leprosy remains unavailable until 
now (1). 
Even now, leprosy treatment is fundamentally 
aimed only at eradication of bacteria, without 
being able to prevent or to cure the damage to the 
peripheral nerve and its components. Early 
detection is hence crucial to determine the 
presence of acid-fast bacteria in Schwann cells (5, 6). 
Mycobacterium leprae causes peripheral nerve 
damage resulting in disability and deformity. Anti-
leprosy medications can indeed eradicate the 
bacteria albeit unable to restore the defects and 
the deformities that have occurred, such as 
recovering the function of a nerve. By 
understanding the mechanism of nerve damage 
caused by Mycobacterium leprae, we can better 
prevent nerve damage (7). 
The WHO divides the levels of disability in 
leprosy patients into 3 degrees, ranging from the 
absence of symptoms to visible damage or 
apparent disability (8). However, peripheral 
nervous disorders may already occur without 
specific leprosy symptoms.  
Schwann cells reside within the peripheral 
nerves. The expression of specific transcription 
factors governs their differentiation. Immature 
Schwann cells will increase the expression of 
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multiple transcription factors such as NFκB, Oct-
6, and Brn2 after receiving signals from axons, 
including NRG1.  
Mycobacterium leprae enter Schwann cells, and 
as self-defense, the cells produce and excrete 
cytokines such as IFN-γ, TNF-α, Erk 1/2 
signalling, Ras, Raf and other inflammatory 
cytokines. Erk 1/2 activate c-Jun, which inhibits 
myelination through Krox-20 down-regulation. 
Krox-20 is a gene crucial in myelin sheath 
synthesis by activating neuregulin (NRG) and 
Neuron Growth Factor (NGF) (9). The initial signs 
of myelin sheath formation in peripheral nerve 
cells are the generation of Myelin Protein Zero 
(MPZ) or protein 0 (P0), and Peripheral Myelin 
Protein 22 (PMP22).  
Previous research indicated that Krox-20 was 
valuable as an early diagnostic tool for peripheral 
nerve defect,(10) and thus, we assumed that 
PMP22, P0, NGF, and NRG1 might also show 
positive correlations as early indicators of 
disability in leprosy patient.  
PMP22 is a tetraspan protein required for 
maintaining myelination stability. Amongst many 
strategies to determine the presence of early 
peripheral nerve damage following Mycobacterium 
leprae infection is to assess Schwann cell 
behaviour by measuring the changes in the myelin 
sheath synthesis markers produced by Schwann 
cells. These include P0, and PMP22. However, up 
to date, there is still no published research that 
discusses the early detection of disability in 
leprosy patients. 
Early identification remains an impediment in 
establishing the diagnosis of disability as leprosy 
sequelae secondary to peripheral nerve cell 
demyelination. It is impossible to restore the 
condition once demyelination begins; therefore 
precautionary endeavours are necessary. An 
understated approach is an early detection of 
possible nerve damage that may occur so that the 
patient can receive immediate preventive 
managements. 
With this research, the authors sought to 
determine the values of PMP22, and P0 as early 
diagnostic tools for disability in leprosy patients. 
 
AIMS 
The study aimed to investigate the validity as 
well as to determine the cut-off points of PMP22 
and P0 as early diagnostic tools of disability in 
leprosy patients. 
METHODS 
We took the samples from ambulatory patients 
visiting the outpatient polyclinic of Kediri Leprosy 
Hospital, Indonesia, during the period of August-
December 2014. The inclusion criteria comprised 
of everyone who showed 0- to 1-degrees of 
disability, aged between 14 to 50 years old, and 
were willing to participate in the research. 
We establish leprosy based on cardinal signs, i.e., 
anaesthetic skin disorder, peripheral nerve 
enlargement with autonomic, sensory and motor 
function abnormalities, and the detection of acid-
fast bacilli on skin scrapings or ear lobes. We based 
the determination of the degrees of disability on 
the WHO criteria published in 1970. ELISA 
examination provided by the Biochemistry-
Biomolecular Laboratory, Faculty of Medicine, 
Brawijaya University, Malang, Indonesia 
measured the PMP22, P0, NGF, and NRG1 levels. 
We analysed the data obtained using SPSS 17 
compatible with Windows® operation system. 
 
RESULTS 
We conducted the study on Multibacillary 
leprosy patients (n=79) with 0- and 1- degrees of 
disability (n=36 and n=43, respectively). The time 
span required for the subject collection at Kediri 
Leprosy Hospital, Indonesia, was five months. We 
briefed each multibacillary leprosy patient who 
met the inclusion criteria about the research. After 
obtaining a signed informed consent, we took a 
biopsy of the skin lesion. We sampled peripheral 
blood for PMP22, and P0 level measurements. 
Two-tailed T-test results showed F = 58.869 with p 
= 0.000 (p <0.05). The differences between plasma 
PMP22 examination results in patients with 0 
versus 1-degrees of disability were significant 
(Figures 1 and 2). The result of 2-tailed T-test in 
P0 level showed F value = 9.909 with p=0,000 
(p<0,05). This showed a significant difference of P0 
plasma level in MB leprosy patients grade 0 and 
grade 1. The cut off value for P0 is 11,40 pg/mL. 
 
 
 
 
 
Figure 1. Plasma PMP22 levels in leprosy 
patients with 0- and 1-degrees of disability 
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Examination of P0 levels in blood revealed 
significant differences in plasma P0 levels between 
multibacillary leprosy patients with 0 versus 1-
degrees of disability. The two-tailed T-test results 
further showed F = 9.909; p = 0,000 (p <0.05) 
(Figures 3 and 4). 
 
 
 
DISCUSSIONS 
This research involved samples taken from 36 
leprosy patients with 0-degree of disability and 43 
leprosy patients with 1-degree of disability. We 
settled on these group based upon the assumption 
that peripheral nerve disorder, which was a 
myelinated disorder caused by Mycobacterium 
leprae infection, would have begun to develop in 
leprosy patients with 1-degrees of disability.  
The sample collection required a period of 
between October - December 2014 in the Leprosy 
Department outpatient clinic at Kediri Leprosy 
Hospital, Indonesia. The age distribution of 
leprosy group with the highest degree of disability 
ranged from 26 to 35 years old (n=13; 36%), whilst 
1-degree of disability was predominant between 36 
to 45 years (n=17; 40% ). A Brazilian study by 
Nardi et. al. revealed that of 232 patients who had 
completed their leprosy treatment, 32% suffer 
from 1- and 2-degrees of disability as per the WHO 
criteria (11).  
Women comprised the highest gender 
distribution (56%) amongst the leprosy patients 
studied with 1-degree of disability. This was in 
accordance with an earlier study by Van Brakel, et. 
al. conducted in Indonesia, which revealed that of 
the overall 1358 patients enrolled, 31.8% are 
leprosy patients with 1-degree of disability (12). 
We employed the WHO criteria (see Table 2) to 
determine the degrees of disability, i.e. 0-, 1-, and 
2-degrees of disability. The study examined 
patients with merely 0- and 1-degrees of disability 
due to its diagnostic nature. We identified 43.54% 
people who suffered from 1-degree of disability out 
of the overall study population (n=79) in the 
Leprosy Department outpatient clinic at Kediri 
Leprosy Hospital, Indonesia. The rest were those 
with 0-degree of disability. The definition of 1-
degree of disability involved anaesthesia of the 
hands and feet in the absence of deformity. Visual 
acuity decrease ought to be no worse than 6/60, or 
a pass in 60-metre finger count test.8  A study by 
Ramos et. al. in 210 leprosy patients on therapy at 
Ethiopia Leprosy Centre revealed that during 
1999-2009, 128 patients (61.5%) had suffered 
disability. Within the group, 26% experienced 1-
degree of disability, whereas 35.6% developed 2-
degree of disability. Moreover, 13.5% acquired eye 
defects, 44.5% were physically handicapped, and 
44.7% procured defects of the lower limbs (13).  
 
PMP22 
Myelin protein expression regulation is an 
intricate process, reflecting the essential tasks of 
the myelin sheath in the nervous system. There is 
a halt in nerve cell proliferation during the 
development and subsequently following an insult 
to the peripheral nervous system; the myelin 
formation ensues thereafter. Myelin protein 
synthesis correlates tightly with that of myelin 
formation during the developmental periods in 
both central- and peripheral nervous system. 
 
Figure 2. ROC curve of plasma PMP22 levels 
 
Figure 3. Plasma P0 levels in leprosy 
patients with 0- and 1-degrees of disability 
 
Figure 4. ROC curve of plasma P0 levels 
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Following a peripheral nervous system lesion, 
myelin protein expression lagged, probably due to 
transcriptional regulation secondary to axonal 
contact loss. Hence, myelin protein synthesis 
progressing on trauma-damaged nerves at a given 
time is tantamount with the remyelination of a 
regenerated axon. Thus, the expression of the 
myelin protein exhibits the same regulatory 
exemplars both at the developmental stages and 
during nerve regeneration (14). 
PMP22 is a 22-kDa myelin protein expressed by 
Schwann cells exclusively in the peripheral 
nervous system and acts as an indispensable 
element of all myelin sheaths therein. 
Furthermore, the PMP22 expression corresponds 
closely with myelin formation during the 
development of the peripheral nervous system and 
thus is closely linked to myelin degradation and 
remyelination processes during the peripheral 
nerve cell regeneration. The central nervous 
system does possess PMP22 albeit in significantly 
minor amounts compared to that within the 
peripheries (14).  
 Within our study, two-tailed T-test 
revealed F = 58.869; p = 0.000 (p <0.05), signifying 
significant differences in plasma PMP22 levels 
between MB leprosy patients with 0- and 1- 
degrees of disability. It confirms that emerging 
nerve deterioration in patients with 1-degree of 
disability resulted in minute amounts of NGF, in 
contrast with those of 0-degree of disability. Snipes 
et. al. confirmed that PMP22 resided exclusively 
within the peripheral nerve myelin sheaths and 
was a product of Schwann cell activities.16 
Consequently, PMP22 is requisite in the myelin 
synthesis in the peripheral nervous system. 
 
P0 Levels 
Protein P0 is the principal structural protein of 
myelin in the peripheral nervous system. It 
belongs to Type-I glycoprotein with a single 
immunoglobulin-like domain and has a molecular 
weight of 30 kDa. The precise mechanism by which 
the mesaxon membrane transforms into myelin 
remains obscure, yet it is clear that the membrane 
insertion with P0 and subsequent homophilic 
bonds in the cis- and trans-orientation excludes 
Myelin Associated Glycoprotein (MAG) and brings 
forth the formation of intact myelin. A single 
myelinating Schwan cell is capable of generating 
several square millimetres of surface membrane. 
The process requires the transcription of the 
myelin protein gene and an exact measure of 
correctly translated protein. The duplication of 
myelin protein genes may occur either naturally or 
inducibly and subsequently triggers demyelination 
that often leads to heavier phenotypes compared to 
null mutations in the same genes. It reflects the 
importance of having the appropriate dose of 
myelin protein gene throughout the myelination 
process (15). 
High levels of P0 are characteristic in the 
differentiation of myelinating Schwann cells. The 
expression of P0 mRNA peaks during the period of 
active peripheral nerve myelination i.e. during the 
first three weeks postpartum in rodents, and is 
maintained at lower sedentary levels unto 
adulthood. P0 gene expression exists during 
Schwann cell development along with the 
expressions of other genes that code for specific 
myelin-forming proteins, such as MBP, PMP-22, 
and MAG. It is worthy to clarify a common 
misconception that oligodendrocytes produce P0 in 
the central nervous system; instead, Schwann cells 
in the peripheral nervous system execute the task 
exclusively. Increased P0 biosynthesis manifests 
early in the myelination process secondary to 
signals associated with the axonal surface. cAMP 
potentially enhances these signals for intracellular 
transduction.  
In this study, we found that two-tailed T-test 
results showed F = 9.909; p = 0.000 (p <0.05), 
implying a significant difference of plasma P0 
levels between MB leprosy patients with 0- and 1-
degrees of disability. Figure 3 displays a 
significant decrease (p <0.05) of P0 level amongst 
the 1-degree of disability group compared with the 
0-degree of disability group. As per 
aforementioned, P0 is a transmembrane 
glycoprotein expressed specifically by Schwann 
cells that occupy the whole myelin. Besides, P0 is 
an adhesion molecule that belongs to the IgG gene 
superfamily and is responsible for maintaining the 
integrity of the myelin membrane through 
interactions between the intracellular and 
extracellular domains. Proteins P0 and PMP22 
collectively form a complex on the myelin 
membrane periphery and in the eukaryotic system 
in vitro. One may observe mutations of the P0 and 
PMP22 genes in hereditary peripheral  neuropathy 
diseases e.g. CMT1A or CMT1B (16). 
These diseases emerge from heterozygous 
genetic mutations and express only low levels of 
sound protein. They exhibit properties in which 
initially, there is normal myelin formation. 
However, subsequent loss of self-integrity that 
leads to eventual demyelination soon follows. It 
suggests that the aforementioned small number of 
functional proteins are incapable of keeping the 
myelin sheath intact. Previous studies support this 
assumption by revealing that heterozygous 
transgenic mice with only one single copy of the P0 
or PMP22 genes exhibit relatively slow onsets of 
myelin deficiency.11 Thus, P0 is a myelin-forming 
protein produced solely by Schwann cells in the 
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peripheral nervous system and plays a vital role in 
the myelination process. 
 
CONCLUDING REMARKS 
Examination of PMP22, P0 levels is invaluable 
in recognising the risk of early disability in leprosy 
patients ahead of clinical symptom 
substantiations, and hence one may employ a 
variety of preventive endeavours for irreversible 
disabilities that morbidly influences numerous 
aspects of patient life. The former appears to 
display higher degrees of sensitivity and specificity 
compared to the latter examination. The 
exploration of other roles of PMP22, P0, NGF, and 
NRG1 in leprosy patients relevant to peripheral 
nerve damage in subclinical and paucibacillary 
leprosy, amongst many, by examining PGL-1 
demands further studies. 
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